OlgaKovalenkoMD

PubMed

• 19 citations
  The miR-181a-SFRP4 axis regulates Wnt activation to drive stemness and platinum resistance in ovarian cancer.
  Anil Belur Nagaraj, Matthew Knarr, Sreeja C. Sekhar, R. Shae Connor, Peronne Joseph, Olga Kovalenko, Alexis Fleming, Arshia Surti, Elmar Nurmemmedov, Luca Beltrame, Se...> ;Cancer Research. 2021 Apr 15
• 2 citations
  Hyperhomocysteinemia and Pulmonary Embolism in a Young Male.
  Olga Kovalenko, Ahmad Nader Kassem, Melissa Jenkins> ;Cureus. 2020 Apr 24
• 2 citations
  The Effect of Forced Cough to Minimize Pain and Discomfort at the Time of Colposcopy-Guided Cervical Biopsy.
  Theresa Kuhn, Adanna Ukazu, Pamela Ohman Strickland, Natalie Roche, Yanille Taveras, Olga A. Kovalenko, Lisa Pompeo, Mark H. Einstein> ;Journal of Lower Genital Tract Disease. 2020 Apr 1
• 8 citations
  Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer.
  Anil Belur Nagaraj, Peronne Joseph, Olga Kovalenko, QuanQiu Wang, Rong Xu, Analisa DiFeo> ;Gynecologic Oncology. 2018 Dec 1
• 11 citations
  Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer
  Anil Belur Nagaraj, Olga Kovalenko, Rita A. Avelar, Peronne Joseph, Annalyn Brown, Arshia Surti, Sandra Mantilla, Analisa DiFeo> ;Clinical Cancer Research. 2018 Sep 15
• 149 citations
  Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
  Anil Belur Nagaraj, Peronne Joseph, Olga Kovalenko, Sareena Singh, Amy Armstrong, Raymond W. Redline, Kimberly Resnick, Kristine M. Zanotti, Steven E. Waggoner, Analis...> ;Oncotarget. 2015 Sep 15
• Join now to see all

Journal Articles

• The miR–181a–SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovaria  
  Belur Nagaraj, A, Knarr M, Sekhar S, Connor R, Joseph P, Kovalenko O, Fleming A, Surti A, Nurmemmedov E, Beltrame L Marchini S, Kahn M, Difeo A, Cancer Research, 4/2021
• Hyperhomocysteinemia and Pulmonary Embolism in a Young Male  
  Kovalenko O, Kassem AN, Jenkins M, Cureus, 2020
• Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer.  
  Belur Nagaraj A, Joseph P, Kovalenko O, Wang Q, Xu R, DiFeo A, Gynecol Oncol, 2018
• Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer.  
  Belur Nagaraj A, Kovalenko O, Avelar R, Joseph P, Brown A, Surti A, Mantilla S, DiFeo A, Clin Cancer Res, 2018
• Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.  
  Nagaraj AB, Wang QQ, Joseph P, Zheng C, Chen Y, Kovalenko O, Singh S, Armstrong A, Resnick K, Zanotti K, Waggoner S, Xu R, DiFeo A, Oncogene, 2017
• Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.  
  Nagaraj AB, Joseph P, Kovalenko O, Singh S, Armstrong A, Redline R, Resnick K, Zanotti K, Waggoner S, DiFeo A, Oncotarget, 2015
• Join now to see all